Composition

Abstract

To provide a composition which has an effect of inhibiting fat accumulation in adipocytes and an effect of activating myoblasts, and which is excellent in the effects of inhibiting fat accumulation and building muscle. The composition of the present invention contains digestible oligosaccharides and at least one member selected from the group consisting of processed plant products, lactic acid bacteria, and polysaccharides.

Description

[Technical Field]

[0001] The present invention relates to a composition containing digestible oligosaccharides and at least one member selected from the group consisting of processed plant products, lactic acid bacteria, and polysaccharides. [Background technology]

[0002] Conventionally, compositions containing processed plant products or polysaccharides have been known as health foods and the like (Patent Document 1). [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Laid-Open No. 2003-267880 Summary of the Invention [Problem to be solved by the invention]

[0004] With regard to compositions used in health foods and the like, consumer needs have become more diverse in recent years, and there is an ever-increasing demand for further improved effects, particularly in terms of health and beauty. However, conventional compositions have not been able to fully meet this demand. [Means for solving the problem]

[0005] Therefore, the present inventors have conducted extensive research into compositions containing at least one selected from a processed plant product, lactic acid bacteria, and polysaccharides to further enhance the health and beauty benefits of the compositions, and have surprisingly found that combining digestible oligosaccharides with at least one selected from a processed plant product, lactic acid bacteria, and polysaccharides inhibits fat accumulation in adipocytes and activates myoblasts, making the compositions useful for dieting and preventing or reducing locomotive syndrome, thereby completing the present invention.

[0006] The present invention is based on the above findings and provides a composition containing digestible oligosaccharides and at least one member selected from the group consisting of processed plant products, lactic acid bacteria, and polysaccharides. [Effects of the Invention]

[0007] The present invention provides a composition that has excellent effects of inhibiting fat accumulation in adipocytes and activating myoblasts. The present invention also provides a diet composition and / or a composition for preventing locomotive syndrome that can inhibit the accumulation of body fat, such as subcutaneous fat and visceral fat, maintain or improve energy metabolic activity, such as lipid decomposition and combustion, reduce or inhibit weight gain, slim down the body, inhibit rebound, build muscle or prevent muscle loss, and improve the efficiency of muscle recovery, by inhibiting fat accumulation in adipocytes and activating myoblasts. DETAILED DESCRIPTION OF THE INVENTION

[0008] The composition of the present invention will be described below based on its preferred embodiments. Hereinafter, the term "composition of the present invention" applies to any of "oral compositions," "oral preparations," "food and drink compositions," "food and drink preparations," and "food and drink" that can be safely ingested, and also applies to any of "diet compositions," "muscle-building compositions," "compositions for preventing muscle loss," "compositions for preventing and / or ameliorating locomotor syndrome," "diet agents," "muscle-building agents," "muscle-loss preventing agents," "agents for preventing and / or ameliorating locomotor syndrome," "diet foods," "muscle-building foods," "foods for preventing muscle loss," and "foods for preventing and / or ameliorating locomotor syndrome" that can safely achieve the effects of the present invention.

[0009] Digestive oligosaccharides The digestible oligosaccharides of the present invention are oligosaccharides of three or more sugars that are decomposed by human digestive enzymes, absorbed in the stomach or small intestine, and converted into energy. The number of constituent sugars of the digestible oligosaccharides usable in the present invention is preferably three to ten, more preferably three to eight, even more preferably three to six, and particularly preferably three to four from the viewpoint of effectiveness. Examples of digestible oligosaccharides include maltooligosaccharides, isomaltooligosaccharides, soybean oligosaccharides, etc., with maltooligosaccharides being particularly preferred from the viewpoints of availability, enhancing the effects of inhibiting fat accumulation in adipocytes and activating myoblasts, and ease of handling during production. Specific examples of maltooligosaccharides include maltotriose, maltotetraose, maltopentaose, maltohexaose, etc., with maltotriose being particularly preferred from the viewpoint of enhancing the effects of the present invention.

[0010] The content of digestible oligosaccharides in the solid content of the composition of the present invention is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, even more preferably 0.01% by mass or more, and particularly preferably 0.05% by mass or more, in terms of effectiveness, in order to further enhance the above-mentioned effect of inhibiting fat accumulation in adipocytes and myoblast activation. Furthermore, the composition of the present invention may consist only of digestible oligosaccharides, processed plant products, lactic acid bacteria, and polysaccharides, but from the viewpoint of enabling high functionality and multi-functionality in combination with other components, the upper limit of the content of digestible oligosaccharides in the composition is preferably 30% by mass or less, more preferably 20% by mass or less, and even more preferably 10% by mass or less.

[0011] ·Plant processed products The processed plant product of the present invention is obtained by subjecting an orally ingestible plant body to one or more of the following processes: drying, crushing, extraction, filtration, squeezing, slurrying, fermentation, heating, etc. Examples of plant body parts include leaves, roots, rhizomes, flowers, stems, fruits, seeds, etc., and the processed plant product may contain one or more parts.

[0012] When a processed plant product is obtained from a plant, the plant is preferably one that has been harvested or processed immediately after harvest. If time is required before processing, the plant is preferably stored by a storage method commonly used by those skilled in the art, such as low-temperature storage, to prevent deterioration of the plant.

[0013] Specific examples of processed plant products include, but are not limited to, dried powders obtained by drying and pulverizing plants (hereinafter also referred to as "dried and pulverized powders"); shredded plant material and its dried product; squeezed plant juice and its dried powder; and plant extract and its dried powder. In the present invention, from the viewpoints of ease of processing, storage, transportation, etc., and versatility of use, it is preferable that the final product be in powder form. In this specification, the term "powder" generally includes any of dried and pulverized powders, dried powders of shredded material, dried powders of squeezed juice, dried powders of extracts, and dried powders of fermented products. Powder naturally includes granular and granular forms.

[0014] Conventionally known methods can be used to dry and pulverize plant bodies into powder. Such methods include a combination of drying and pulverization of plant bodies. Either the drying or pulverization process can be performed first, but it is preferable to perform the drying process first. The drying and pulverization process may further include one or more treatments selected from blanching, cooling, sterilization, and the like, as needed. The pulverization process may be performed two or more times, and it is preferable to perform a coarse pulverization process followed by a fine pulverization process for more fine pulverization.

[0015] The drying treatment is not particularly limited, but is preferably a treatment to dry the barley stems and leaves to a moisture content of 10% by mass or less, particularly 5% by mass or less, for example. This drying treatment can be carried out by any method known to those skilled in the art, such as hot air drying, high-pressure steam drying, electromagnetic wave drying, freeze-drying, etc.

[0016] The grinding process is not particularly limited, but examples include grinding the plant body by any method commonly used by those skilled in the art using grinding equipment or tools such as a crusher, mill, blender, or stone mill. The ground plant body is sieved as needed, and it is preferable to use plant body powder that passes through a 30 to 250 mesh sieve, for example. By using a particle size that passes through a 250 mesh or smaller, the plant body powder becomes easier to handle during further processing, and by using a particle size that passes through a 30 mesh or larger, the plant body powder can be easily mixed uniformly with other materials.

[0017] Specific methods for drying and pulverizing include, for example, cutting the plant body, drying it so that the moisture content is 10% by mass or less, and then pulverizing it. Other methods include, for example, cutting the plant body, rolling it, drying it, and pulverizing it; drying the plant body, coarsely pulverizing it, heating it at 110°C or higher, and then finely pulverizing it.

[0018] Furthermore, the method for shredding the plant body is not particularly limited, and methods commonly used by those skilled in the art for shredding a plant body, such as slicing, crushing, or chopping, can be used. One example of shredding is slurrying. Slurrying can be performed by subjecting the plant body to a mixer, juicer, blender, mass colloider, or the like to create a mushy gruel (a suspension of liquid and solids). When shredded seeds are heated, the liquid can be boiled down with water, and the coarse solids can be removed by sieving, filtration, or the like, and the liquid can be used.

[0019] The method for extracting juice from a plant body is not particularly limited, and examples thereof include squeezing the plant body or a shredded product thereof, and centrifuging or filtering the shredded product of the plant body. Specific examples of the juicing method include a method in which the juice is extracted using a mechanical crushing means such as a mixer or juicer, and then, if necessary, removing coarse solids by means such as sieving or filtration to obtain a squeezed juice. The squeezed juice may be concentrated or dried and powdered as necessary. When powdering, an excipient may be used as necessary.

[0020] The method for obtaining a plant extract is not particularly limited, but examples include a method in which an extraction solvent commonly used by those skilled in the art, such as ethanol, water, methanol, ethyl acetate, or acetone, is added to the plant, or its finely ground or dried product, and the mixture is stirred and / or heated as needed to extract. One or more extraction solvents can be appropriately selected and used as needed. When heating, the temperature is not particularly limited as long as it is between room temperature and the boiling point of the solvent. It is preferable to use an extract from which coarse solids have been removed by means of sieving, filtration, or the like. For example, the filtrate (extract) obtained by adding water to finely ground soybeans (ground product) and boiling it down, followed by filtration, is known as soy milk. The extract may be concentrated as needed, or dried and powdered. When powdering, an excipient can be used as needed.

[0021] When the processed plant product is in powder form, it is preferable that the moisture content be 20% by mass or less, particularly 10% by mass or less, from the viewpoints of stability and prevention of quality deterioration, etc. For example, a moisture content of 1% by mass or more is preferable from the viewpoint of ease of production of the powdered processed plant product.

[0022] When the processed plant product is in a powder form, it is preferable that the powder pass through a 30 to 250 mesh sieve, from the viewpoints of ease of mixing with other ingredients, ease of oral administration, etc. From the same viewpoint, it is more preferable that 90% by mass or more of the processed plant product in a powder form pass through a 200 mesh sieve.

[0023] The processed plant product of the present invention may be a commercially available product, for example, the products described in the Examples below.

[0024] The plant body in the processed plant product is preferably a processed product of green leaves. In the present invention, green leaves are leaves and / or stems of green plants that can be orally ingested and contain chlorophyll. The green leaves that can be used in the present invention include, for example, those of Gramineae, Asteraceae, Umbelliferae, Moraceae, Houttuynia cordata, Lamiaceae, Liliaceae, Tilia, Convolvulaceae, and Theaceae, which are preferred because they have high fat accumulation inhibitory activity in adipocytes, high myoblast activation activity, and can provide plant-derived nutrients. Examples of Gramineae include wheat, durum wheat, rye, triticale, barley, oats, Job's tears, corn, rice, barnyard millet, foxtail millet, and bracken. Examples of Asteraceae include mugwort. Examples of Umbelliferae include Angelica keiskei, parsley, celery, and choumeisou (also known as Peucedanum japonicum). Examples of Moraceae include mulberry. Examples of Houttuynia cordata include Houttuynia cordata. Examples of Lamiaceae include perilla. Examples of Brassicaceae plants include komatsuna, kale, cabbage, and broccoli. Examples of Liliaceae plants include asparagus. Examples of Tiliaceae plants include mulukhiyah. Examples of Convolvulaceae plants include sweet potato. Examples of Theaceae plants include tea. Among these, barley, kale, chomeiso, kumazasa, tea, angelica tree, mulberry, sweet potato, mugwort, and cabbage are particularly preferred in terms of effectiveness.

[0025] When the green leaves used in the present invention are barley leaves, it is preferable to use young barley leaves. Young barley leaves are leaves and / or stems harvested before maturity, i.e., from the time when tillers start to the time when heading starts. Also, if the green leaves are sweet potatoes, the leaves and / or It is preferable to use leaves including stems, and young sweet potato leaves are particularly preferable.

[0026] When the plant body is green leaves, the green leaves are preferably in the form of dried and pulverized powder. As described above, the dried and pulverized powder is a dry powder obtained by drying and pulverizing a plant body that has not been subjected to juice squeezing or extraction processes.

[0027] The processed plant products of the present invention also include fermented plants because of their high lipid accumulation-inhibiting activity in adipocytes and myoblast-activating activity. Plants that can be used for the fermented plant products include the various plants listed above as examples of processed green leaves, as well as other vegetables, mushrooms, grains, seeds, beans, fruits, seaweed, wild plants, etc. Specific examples of other vegetables, mushrooms, grains, seeds, beans, fruits, seaweed, and wild plants include burdock, carrots, lotus root, cabbage, pumpkin, radish, tomato, bell pepper, shiitake mushroom, barley, millet, brown rice, Job's Pen, corn, sesame, soybeans, kidney beans, pineapple, bananas, apples, lemons, melons, prunes, kiwi, kelp, wakame seaweed, Gynostemma pentaphyllum, horsetail, muira puama, and cat's claw. These can be used alone or in combination of two or more. When the processed plant product is a fermented product, the plant body is preferably a fermented product of 5 or more, more preferably 10 or more, more preferably 20 or more, and particularly preferably 40 or more types of plant body selected from vegetables such as cabbage, mushrooms, grains, seeds, beans, fruits, seaweed, and wild plants. As the fermented processed plant product, for example, commercially available fermented products called "fermented plant extract" or "fermented wild plant extract" may be used.

[0028] When the processed plant product is a fermented product, the fermented product may be in any of the following forms: liquid, slurry, paste, or powder. Fermented products of plants include those obtained by fermenting the plant or its pulverized product, juice, extract, or shredded product. When the product after fermentation is in the form of a liquid, slurry, or paste, it can be dried by any method known to those skilled in the art, such as hot air drying, high-pressure steam drying, electromagnetic wave drying, or freeze-drying. In this case, an excipient may be added, and the product may be dried and then pulverized to form a dry powder.

[0029] Fermented products of plants can be obtained, for example, by adding lactic acid bacteria, yeast, koji mold, natto bacteria, acetic acid bacteria, etc. to the plant or its pulverized product, shredded product, juice, or extract. These may be used alone or in combination of two or more species, and when two or more species are used, they may be added simultaneously or different species may be added in stages. It is preferable that the bacteria used for fermentation be at least one species selected from lactic acid bacteria, yeast, and acetic acid bacteria, since useful components such as physiologically active substances produced by these species can be ingested.

[0030] Lactic acid bacteria used for fermentation refer to bacteria that produce lactic acid through metabolism, and specific examples include bacteria described as lactic acid bacteria that can be used in the present invention. Examples of yeasts used for fermentation include sake yeast, wine yeast, brewer's yeast, and baker's yeast. For example, yeasts belonging to the genera Saccharomyces and Schizosaccharomyces are used, with Saccharomyces cerevisiae, Saccharomyces pastorianus, and Schizosaccharomyces pombe being preferred. Saccharomyces cerevisiae and its isolated strains are particularly preferred for their ability to produce useful substances such as amino acids and vitamins. Examples of koji molds used for fermentation include black koji mold, white koji mold, yellow koji mold, and red koji mold, and commercially available products can be used. Specific examples include microorganisms belonging to the genus Aspergillus, such as Aspergillus awamori (black koji mold), Aspergillus saitoi (black koji mold), Aspergillus nakazawai (black koji mold), Aspergillus usamii (black koji mold), Aspergillus luchensis (black koji mold), Aspergillus niger (black koji mold), Aspergillus kawachii (white koji mold), and Aspergillus oryzae (yellow koji mold). Examples of acetic acid bacteria include microorganisms belonging to the genus Acetobacter, such as Acetobacter aceti, Acetobacter pasteurianus, and Acetobacter hansenii. Examples of natto bacteria include bacteria of the genus Bacillus, such as Bacillus natto, Bacillus subtilis, and Bacillus circulans.

[0031] ·Lactic acid bacteria The lactic acid bacteria of the present invention refer to bacteria that produce lactic acid through metabolism. The lactic acid bacteria that can be used in the present invention may be live or killed, and in the case of killed bacteria, the cells may be disrupted. Lactic acid bacteria powder can be obtained, for example, by removing unnecessary components such as the medium from cultured lactic acid bacteria or from a lactic acid bacteria culture used in fermentation, and then powdering the lactic acid bacteria cells using a known method. The type of lactic acid bacteria is not particularly limited as long as it produces lactic acid as a metabolic product, and includes those that have traditionally been orally ingested by animals such as humans, such as those belonging to the genera Bifidobacterium, Lactobacillus, Enterococcus, Leuconostoc, Pediococcus, Staphylococcus, Tetragenococcus, and Bacillus. Examples of the genus Bifidobacterium include Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium adolescentis, and Bifidobacterium mongoliense. Lactobacillus genus includes Lactobacillus brevis, Lactobacillus gasseri, Lactobacillus acidophilus, Lactobacillus buchneri, Lactobacillus bulgaricus, Lactobacillus delburvecki, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus curvatus, Lactobacillus halivaticus, Lactobacillus Examples include Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus sporogenes, Lactobacillus sakei, Lactobacillus fructivorans, Lactobacillus hilgardii, Lactobacillus reuteri, and Lactobacillus fermentum. Enterococcus includes Enterococcus faecalis (sometimes called Streptococcus faecalis), Enterococcus faesium (sometimes called Streptococcus faesium), Streptococcus thermophilus, and Lactococcus lactis (sometimes called Streptococcus lactis). The genus Leuconostoc includes Leuconostoc mesenteroides and Leuconostoc oenos. The genus Pediococcus includes Pediococcus acidilactici and Pediococcus pentosaceus. Examples of the genus Staphylococcus include Staphylococcus carnosus and Staphylococcus xylosus. The genus Tetragenococcus includes Tetragenococcus halophilus. Examples of the genus Bacillus include Bacillus coagulans and Bacillus mesentericus. Among these, Bacillus coagulans, Enterococcus faecalis, and Bifidobacterium bifidum are preferred because of their high effects of inhibiting fat accumulation in adipocytes and activating myoblasts. These may be used alone or in combination of two or more.

[0032] ·Polysaccharide The polysaccharides of the present invention are those that are not digested or are extremely difficult to digest (resistant to digestion) by human digestive enzymes. Examples of polysaccharides that can be used in the present invention include raffinose, fructooligosaccharides, galactooligosaccharides, soybean oligosaccharides, xylooligosaccharides, polydextrose, resistant dextrin, psyllium, pectin, arabinoglucan, xylan, galactomannan, glucomannan, galactan, tamarind gum, xanthan gum, etc., and polydextrose, resistant dextrin, tamarind gum, xanthan gum, etc. are preferred. Examples of water-soluble dietary fibers include psyllium, pectin, arabinoglucan, xylan, galactomannan, glucomannan, galactan, tamarind gum, and xanthan gum. Examples of water-soluble dietary fibers include polydextrose, indigestible dextrin, tamarind gum, and xanthan gum, and more preferably polydextrose, indigestible dextrin, xanthan gum, and tamarind gum. Xanthan gum and tamarind gum are particularly preferred because of their high effect of inhibiting fat accumulation in adipocytes and myoblast activation.

[0033] The contents of the processed plant product, lactic acid bacteria, and polysaccharides in the present invention are not particularly limited, but from the viewpoint of further enhancing the effect of inhibiting fat accumulation in adipocytes and the effect of activating myoblasts, the total content of the processed plant product, lactic acid bacteria, and polysaccharides in the solid content of the composition of the present invention is preferably 10% by mass or more, more preferably 20% by mass or more, even more preferably 30% by mass or more, and particularly preferably 40% by mass or more in terms of effectiveness, in terms of dry mass. Furthermore, the composition of the present invention may consist only of digestible oligosaccharides, processed plant product, lactic acid bacteria, and polysaccharides, but from the viewpoint of enabling high functionality and multi-functionality in combination with other components, the upper limit of the content of the processed plant product, lactic acid bacteria, and polysaccharides in the composition is preferably 90% by mass or less, more preferably 80% by mass or less, and even more preferably 70% by mass or less. The total amount of plant processed products, lactic acid bacteria, and polysaccharides in the composition referred to here refers to the amount of each plant processed product, lactic acid bacteria, or polysaccharide if only one type of plant processed product, lactic acid bacteria, or polysaccharide is contained, and refers to the total amount if two or more types of these are contained.

[0034] In terms of inhibiting lipid accumulation in adipocytes and activating myoblasts, the mass ratio of digestible oligosaccharides to the total amount of processed plant products, lactic acid bacteria, and polysaccharides per 1 part by mass of digestible oligosaccharides in the composition of the present invention is preferably 0.01 parts by mass or more, more preferably 0.1 parts by mass or more and 10,000 parts by mass or less, even more preferably 1 part by mass or more and 1,000 parts by mass or less, and particularly preferably 5 parts by mass or more and 600 parts by mass or less from the standpoint of effectiveness.

[0035] In particular, from the standpoint of further enhancing the fat accumulation prevention effect and myoblast activation activity, the mass ratio of digestible oligosaccharides to processed green leaf products is preferably 1 part by mass or more of each processed product by dry mass to 1 part by mass of digestible oligosaccharides, more preferably 25 parts by mass or more and 10,000 parts by mass or less, even more preferably 50 parts by mass or more and 1,000 parts by mass or less, and particularly preferably 100 parts by mass or more and 500 parts by mass or less from the standpoint of effectiveness. For the same reasons, the mass ratio of digestible oligosaccharides to plant fermentation products is preferably 0.01 mass parts or more of plant fermentation products per 1 mass part of digestible oligosaccharides, more preferably 0.01 mass parts or more and 100 mass parts or less, even more preferably 0.1 mass parts or more and 50 mass parts or less, and particularly preferably 1 mass part or more and 10 mass parts or less from the standpoint of effectiveness. For the same reasons, the mass ratio of digestive oligosaccharides to lactic acid bacteria is preferably 0.0001 to 100 parts by mass, more preferably 0.001 to 50 parts by mass, and particularly preferably 0.01 to 20 parts by mass, in terms of effectiveness, of lactic acid bacteria per 1 part by mass of digestive oligosaccharides. For the same reasons, the mass ratio of digestible oligosaccharides to polysaccharides is preferably 0.1 mass parts or more of polysaccharides per 1 mass part of digestible oligosaccharides, more preferably 1 mass part or more and 5,000 mass parts or less, even more preferably 10 mass parts or more and 1,000 mass parts or less, and particularly preferably 20 mass parts or more and 500 mass parts or less from the standpoint of effectiveness.

[0036] The composition of the present invention may contain other ingredients in addition to digestible oligosaccharides, processed plant products, lactic acid bacteria, and polysaccharides. Examples of such other ingredients include vitamins, proteins, minerals, dairy products, citric acid, acidulants, colorants, and glossing agents, as well as manufacturing agents such as talc and calcium stearate. Other ingredients include various excipients, binders, lubricants, stabilizers, diluents, bulking agents, emulsifiers, colorants, flavorings, food additives, and seasonings. The content of such other ingredients can be appropriately selected depending on the form of the composition. In this embodiment, the components other than the digestible oligosaccharides, processed plant products, lactic acid bacteria, and polysaccharides contained in the composition are preferably 50% by mass or less of the solid content, more preferably 30% by mass or less, and particularly preferably 10% by mass or less from the viewpoint of effectiveness.

[0037] The composition of the present invention may be in any form, such as a solid, semi-solid, or fluid. For example, solid forms include powder, granules, granules, tablets, capsules, rods, plates, blocks, solids, rounds, candies, gummies, wafers, biscuits, cookies, cakes, and chewable forms. Semi-solid forms include pastes and jellies. Fluid forms include syrups, liquids, and jellies.

[0038] In addition, the composition of the present invention is preferably in the form of powder, fine granules, or granules, and is mixed with water for oral intake, since this prevents spoilage and is suitable for long-term storage.In addition, when the composition of the present invention is in the form of a solid, as described above, it can be mixed with water to form a liquid, and then the liquid can be taken orally, for example, by drinking.However, depending on the preference of the user, the solid can also be taken orally.In addition to water, it can be added to milk, soy milk, fruit juice drinks, whey drinks, soft drinks, yogurt, pancake mix, etc., and used.It can also be used as a supplement, health food, nutrient-functional food, functional food, food with specified health uses, and pharmaceuticals.

[0039] The composition of the present invention is an oral composition, and when the composition contains processed green leaves as the processed plant product, it is preferable to use the composition of the present invention as an edible or drinkable composition for green juice. An edible or drinkable composition for green juice is a beverage containing processed green leaves. Examples of edible or drinkable compositions for green juice include the beverage and a solid that is dispersed or dissolved in a liquid to obtain the beverage. In addition to commonly known green juice products, edible or drinkable compositions for green juice include smoothies, jellies, and the like.

[0040] The form of the composition of the present invention is not limited to the beverages given as examples of edible compositions for green juice and the solid form that is dispersed or dissolved in a liquid to obtain this beverage, and any form can be adopted.

[0041] As described in the Examples below, the green leaf powder of the present invention contains digestible oligosaccharides and at least one selected from the group consisting of processed plant products, lactic acid bacteria, and polysaccharides, thereby exhibiting excellent effects of inhibiting fat accumulation in adipocytes and / or activating myoblasts. Specifically, ingesting a composition containing digestible oligosaccharides and at least one selected from the group consisting of processed plant products, lactic acid bacteria, and polysaccharides can prevent lipid accumulation in adipocytes and activate myoblasts in skeletal muscle, etc. Therefore, ingesting the composition of the present invention can prevent body fat accumulation, reduce body fat, maintain or promote energy metabolism in muscles, promote muscle growth, prevent muscle wasting and loss, be used for dieting, and prevent or improve locomotive syndrome, etc. That is, the composition of the present invention can be excellent for preventing body fat accumulation, reducing body fat, activating myoblasts, promoting muscle cell proliferation, building muscle, preventing muscle loss, preventing muscle wasting, promoting metabolism, preventing obesity, preventing obesity, eliminating obesity, reducing or suppressing weight gain, slimming the body, preventing rebound, dieting, and preventing and / or improving locomotive syndrome, etc. Here, building muscle means increasing muscle mass, and preventing muscle loss means preventing muscle mass loss. [Example]

[0042] The present invention will be explained in more detail below by showing examples, but the scope of the present invention is not limited to these examples.

[0043] [Examples 1 to 20, Comparative Examples 1 to 24] The test samples used in Tables 1 and 2 were as follows: Maltotriose: A commercially available powdered product was used. Trehalose: A commercially available powdered product was used. Young barley leaves: Dried and crushed powder of young barley leaves manufactured by Toyo Shinyaku Co., Ltd. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Kale: Dried and crushed powder of kale leaves manufactured by Toyo Shinyaku Co., Ltd. was used. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh sieve and a moisture content of 1% to 7% by mass. Chomeisou: Dried and crushed powder of Chomeisou leaves manufactured by Toyo Shinyaku Co., Ltd. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Kumazasa: Commercially available dried and crushed Kumazasa leaves were used. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Matcha: Dried and ground powder of Tencha manufactured by Toyo Shinyaku Co., Ltd. was used. The dried and ground powder had 90% or more by mass of powder passing through a 200 mesh sieve and a moisture content of 1% to 7% by mass. Angelica keiskei: Commercially available dried and crushed powder of Angelica keiskei leaves was used. The dried and crushed powder had 90% or more by mass of particles passing through a 200 mesh sieve and a moisture content of 1% to 7% by mass. Mulberry: Dried and crushed powder of mulberry leaves manufactured by Toyo Shinyaku Co., Ltd. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Young sweet potato leaves: Dried and crushed powder of sweet potato leaves manufactured by Toyo Shinyaku Co., Ltd. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Mugwort: Dried and crushed mugwort leaves manufactured by Toyo Shinyaku Co., Ltd. were used. The dried and crushed powder had 90% or more by mass of material passing through a 200 mesh and a moisture content of 1% to 7% by mass. Spore-forming lactic acid bacteria: Commercially available dried powder of spores of the scientific name Bacillus coagulans was used. Lactic acid bacteria (killed bacteria): Commercially available dried powder of killed bacteria of the scientific name Enterococcus faecalis was used. Lactic acid bacteria (mixture): A commercially available mixture of dry powders of live bacteria with the scientific names Enterococcus faecium and Bifidobacterium bifidum was used. Polydextrose: Commercially available polydextrose (powder) with a dietary fiber content of 90% or more by mass was used. · Resistant dextrin: Commercially available resistant dextrin (powder) with a dietary fiber content of 85 to 95% by mass was used. Xanthan gum: Commercially available xanthan gum (powder) derived from Xanthomonas Campestris was used. Tamarind gum: Commercially available tamarind gum (dried powder) derived from tamarind seeds was used. Fermented cabbage extract: Toyo Shinyaku Co., Ltd.'s product name "Fermented cabbage extract" (dried and crushed powder made by fermenting raw cabbage with lactic acid bacteria, then drying and crushing) was used. Multi-plant fermented extract: A commercially available multi-plant fermented extract (raw materials including burdock, carrot, lotus root, cabbage, pumpkin, radish, tomato, bell pepper, shiitake mushroom, barley, millet, brown rice, pearl barley, corn, sesame, soybean, kidney bean, pineapple, banana, apple, lemon, melon, prune, kiwi, kelp, wakame seaweed, gynostemma pentaphyllum, horsetail, muira puama, cat's claw, etc., more than 80 kinds of vegetables, fruits, grains and wild plants are fermented with lactic acid bacteria, yeast and acetic acid bacteria, and then the fermented material is dried and powdered) was used.

[0044] The test samples were subjected to a fat accumulation test according to the following procedures (a) to (L). [Fat accumulation test] (a) 75 cm in a 37°C, 5% CO2 incubator 2 Mouse fibroblast cells 3T3-L1 were cultured in a flask in DMEM medium containing 10% (v / v) FBS. (b) Fibroblast 3TL-L1 cells were suspended by trypsinization and dispersed to a 75 cm 2Transfer 2x10 cells from the flask to each well of a 96-well plate. 4 Cells were seeded at a cell density of 1000 cells / well and pre-cultured for 2 days in a 37°C, 5% CO2 incubator in DMEM medium containing 10% (v / v) FBS. The medium was then replaced with differentiation-inducing medium containing the test sample (control: differentiation-inducing medium only), and differentiation was induced for 3 days. The differentiation-inducing medium used was DMEM medium containing 10% (v / v) FBS containing 0.5 mM isobutylmethylxanthine, 0.5 μM dexamethasone, and 10 μg / mL insulin. The test samples were prepared in the differentiation-inducing medium to achieve a predetermined concentration (300 μg / mL). Tables 1 and 2 show the mass percentage of each test sample relative to the total test sample. (c) The differentiation-inducing medium was replaced with a differentiation-maintenance medium containing the test sample (control was differentiation-maintenance medium only), and the cells were cultured for 4 days. The differentiation-maintenance medium used was a 10% (v / v) FBS-containing DMEM medium containing 10 μg / mL insulin. The test samples were prepared in the differentiation-maintenance medium so that the total amount reached a predetermined concentration (300 μg / mL). Tables 1 and 2 show the mass percentage of each test sample in the total amount of test sample. (d) After culturing in (c), the culture medium supernatant was removed from the adipocytes. Next, 10% (v / v) formalin-containing PBS was added to the cells in an equal volume to the culture medium, and the cells were left to stand at room temperature for 10 minutes in the dark. The formalin solution was then removed from the cells, and the cells were washed once with PBS. (e) 100 μL / well of 10% (v / v) formalin-containing PBS was added to the cells, and the cells were left to stand at room temperature for 10 minutes in the dark to fix the cells. (f) The formalin solution was removed, and the sections were washed twice with PBS. (g) 50 μL / well of a 60% by volume solution of 3 mg / mL oil red in isopropanol (staining solution) was added to the adipocytes and blank wells, and the cells were stained for 30 minutes at room temperature in the dark. The staining solution was then removed, and 150 μL / well of a 60% by volume aqueous isopropanol solution was added, washing the cells twice. (h) 100% by volume isopropanol was added to the cells and blank wells at 100 μL / well and shaken for approximately 10 minutes to extract the staining solution. The absorbance of the isopropanol solution from which the staining solution had been extracted was measured at 520 nm and 650 nm. (k) After completely removing the isopropanol solution by air drying, TM The protein amount of each cell was calculated using a BCA Protein Assay kit (Thermo Fisher Scientific). (L) The amount of fat accumulation per protein was calculated using the formula below, and the relative values ​​to the control were calculated. The results are shown in Tables 1 and 2. A smaller relative value indicates greater inhibition of fat accumulation in adipocytes. Relative fat accumulation (%) = [[(Abs520 sample - Abs520 blank) - (Abs650 sample - Abs650 blank)] / (Protein sample)] / [(Abs520 control - Abs520 blank) - (Abs650 control - Abs650 blank)] / (Protein control)]] × 100 (%) Abs520 sample, Abs650 sample: absorbance of each example or comparative example at 520 nm and 650 nm Abs520 control, Abs650 control: Absorbance of control at 520nm and 650nm Abs520 blank, Abs650 blank: Blank absorbance at 520nm and 650nm Protein sample: Amount of protein in the cells in each example or comparative example Protein control: The amount of protein in the cells in the control

[0045] [Table 1]

[0046] [Table 2]

[0047] It is generally known that differentiation of fibroblasts induces the expression of PPARγ, which stimulates fat synthesis and causes fat accumulation within the cells, resulting in large, round adipocytes. As shown in Table 1, the compositions of each example, which combined digestible oligosaccharides with at least one selected from processed plant products, lactic acid bacteria, and polysaccharides, had low relative absorbance values ​​(turbidity), indicating that less fat had accumulated in the adipocytes. In contrast, the compositions containing only digestible oligosaccharides (Comparative Example 1), or only processed plant products, lactic acid bacteria, or polysaccharides (Comparative Examples 2 to 18), and the compositions combining trehalose and processed plant products (Comparative Examples 19 to 20) had high relative absorbance values ​​(turbidity), indicating that more fat had accumulated in the adipocytes. From the above, it was shown that by combining digestible oligosaccharides with at least one selected from plant processed products, lactic acid bacteria, and polysaccharides, fat accumulation in adipocytes can be effectively suppressed and obesity can be prevented.

[0048] [Examples 21 to 39, Comparative Examples 25 to 36] Each of the above test sample powders was subjected to a myoblast activation test according to the following procedures (1) to (7). [Myoblast activation test] (1) Mouse skeletal muscle-derived myoblasts (product name: C2C12, manufactured by RIKEN BioResource Center) were cultured in a 75 cm culture medium containing 10 vol% FBS in a 5% CO incubator at 37°C. 2 The cells were cultured in flasks. (2) After culturing in (1), trypsinized cells were suspended and plated at 75 cm 2 The cells were harvested from the flask, counted, and then seeded in a collagen-coated 96-well plate at a cell density of 2000 cells / well in the medium, followed by pre-culture for 24 hours in a 37°C, 5% CO2 incubator. (3) Separately from (1) and (2), the powders marked with "●" in Table 3 or Table 4 were dispersed or dissolved in 10 vol% FBS-containing DMEM medium to the concentrations shown in the left column of Table 3 or Table 4, respectively, to prepare solutions. The resulting solutions were filter-sterilized using a 0.2 μm filter (manufactured by Advantec) and used as sample solutions. However, for spore-forming lactic acid bacteria, lactic acid bacteria (killed bacteria), and bifidobacteria, the sample solutions were prepared by dispersing them. As a control, 10 vol% FBS-containing DMEM medium itself was used as the sample solution. (4) After removing the medium from each well, 200 μL of the sample solution prepared in (3) was added to each well, and the plates were cultured in a 37°C, 5% by volume CO 2 incubator for 24 hours. (5) After the incubation in (4), the medium was removed and each well was washed once with 200 μL / well of PBS. Then, 150 μL / well of Cell Counting Kit-8 solution (Dojindo Laboratories) diluted 30-fold with serum-free DMEM was added. (6) After adding the solution from (5), the plate was placed in a 37°C, 5% CO2 incubator to allow color development to occur. The absorbance of each well was then measured at 450 nm. Based on the data obtained, the percentage of cells relative to the control (% of control) was calculated using the following formula, and this was used as the myoblast-stimulating activity. % of control=(Data sample - Data blank) / (Data control - Data blank)×100 Data sample: absorbance of each example or comparative example Data control: control absorbance Data blank: Absorbance when no cells are present

[0049] (7) Evaluation The calculation results of the percentage of cell counts for each Example and Comparative Example, with the control set at 100%, are summarized in Tables 3 and 4. In Tables 3 and 4, a black circle indicates that the sample solution of the Example or Comparative Example contained the test sample in the left column at the concentration shown in the left column.

[0050] [Table 3]

[0051] [Table 4]

[0052] As shown in Table 3, the compositions of each Example, which combined digestible oligosaccharides with at least one selected from processed plant products, lactic acid bacteria, and polysaccharides, exhibited a myoblast-activating effect. In contrast, as shown in Table 4, the compositions containing only digestible oligosaccharides (Comparative Examples 25 and 26), the compositions containing trehalose and processed plant products (Comparative Example 27), and the compositions containing only processed plant products, lactic acid bacteria, or polysaccharides, or only polysaccharides (Comparative Examples 28 to 36), did not exhibit a myoblast-activating effect. From the above, it was shown that by combining digestible oligosaccharides with at least one selected from lactic acid bacteria and polysaccharides, myoblasts are effectively activated and energy metabolism in muscle tissue is enhanced.

[0053] Example 40 (Production of a composition for green juice) Raw materials were prepared according to the blending ratios described in the following formulation examples, and a composition for green juice exhibiting the effects of the present invention was manufactured.

[0054] [Table 5]

[0055] Example 41 (Production of a composition for green juice) Raw materials were prepared according to the blending ratios described in the following formulation examples, and a composition for green juice exhibiting the effects of the present invention was manufactured.

[0056] [Table 6]

[0057] Example 42 (Production of a composition for green juice) Raw materials were prepared according to the blending ratios described in the following formulation examples, and a composition for green juice exhibiting the effects of the present invention was manufactured.

[0058] [Table 7]

[0059] Example 43 (Production of a composition for green juice) Raw materials were prepared according to the blending ratios described in the following formulation examples, and a composition for green juice exhibiting the effects of the present invention was manufactured.

[0060] [Table 8]

[0061] Example 44 (Production of a composition for green juice) Raw materials were prepared according to the blending ratios described in the following formulation examples, and a composition for green juice exhibiting the effects of the present invention was manufactured.

[0062] [Table 9]

[0063] Example 45 (Production of tablets) After preparing the raw materials according to the compounding ratios described in the following prescription examples, tablets exhibiting the effects of the present invention were produced using a tableting machine.

[0064] [Table 10]

Claims

[Claim 1] The invention described in the specification.

Images